ScreenerHero
BINVBioInvent International AB
STO · SE · Healthcare · Biotechnology · bioinvent.com
23.10SEK+0.43%Mkt Cap: 144.77M $P/E: —

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
ARWR
Arrowhead Pharmaceuticals, Inc.
$12.59BUSD

Key Statistics

Company
Market Cap144.77M $
Enterprise Value101.70M $
Revenue (TTM)20.84M $
Gross Profit20.84M $
Net Income (TTM)-31.84M $
Revenue/Share0.3167 USD
Last Price23.10 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees112
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0015244520
Valuation
P/E (Trailing)—
P/E (Forward)-5.84
PEG0.27
EV/EBITDA-3.14
EV/Revenue4.88
P/S6.93
P/B3.44
EPS (TTM)-5.10
EPS (Forward)-3.93
52W Range
20.8512% of range39.30
52W High39.30 SEK
52W Low20.85 SEK
Profitability
Gross Margin100.00%
Oper. Margin-907.23%
EBITDA Margin-155.52%
Profit Margin-146.96%
ROE-59.69%
ROA-49.59%
Growth
Revenue Growth-39.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.70M $
CapEx (TTM)694.43K $
FCF Margin-73.63%
FCF Yield-10.60%
Net Debt-43.06M $
Net Debt/EBITDA1.33
Balance Sheet
Debt/Equity0.02
Current Ratio5.32
Quick Ratio5.20
Book Value/Sh6.673 SEK
Cash/Share6.937 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateDec 14, 2020
Analyst Consensus
Rating—
Target (Mean)95.00 SEK
Upside (mean)+311.3%
Target Range85.00 SEK – 110.00 SEK
SEK85.00+311.3% to meanSEK110.00
# Analysts3
Ownership
Shares Out.65.80M
Float31.44M
Insiders10.17%
Institutions57.84%
Technical
SMA 5023.48 (-1.6%)
SMA 20025.70 (-10.1%)
Beta0.02
S&P 52W Chg18.16%
Avg Vol (30d)71.01K
Avg Vol (10d)114.81K
Technical Indicators
RSI (14)47.0
MACD0.0133
MACD Signal-0.1200
MACD Hist.+0.1333
BB Upper24.65 SEK
BB Middle23.15 SEK
BB Lower21.65 SEK
BB Width12.97%
ATR (14)1.152 SEK
Vol Ratio (20d)1.82x